Alpharmaxim logo in white

Access a revolutionary new report
addressing complex barriers to
treatment change in Parkinson’s

Access a revolutionary new report addressing complex barriers to treatment change in Parkinson’s.

This report uses leading behavioural science approaches to transform how you plan and deliver communications for Parkinson’s.

Parkinson’s remains one of the greatest challenges in medicine. Current therapies focus on symptoms. New treatments have failed to meet expectations. These all lead to complex barriers to adoption.

Yet with 139 treatments in clinical trials, it’s crucial to communicate effectively more than ever to ensure any new treatment is adopted.

Click REGISTER INTEREST to stay updated on the report's availability or request a free summary

Access a revolutionary new report addressing complex barriers to treatment change in Parkinson’s

This report uses leading behavioural science approaches to transform how you plan and deliver communications for Parkinson’s.

Parkinson’s remains one of the greatest challenges in medicine. Current therapies focus on symptoms. New treatments have failed to meet expectations. These all lead to complex barriers to adoption.

Yet with 139 treatments in clinical trials, it’s crucial to communicate effectively more than ever to ensure any new treatment is adopted.

Click REGISTER INTEREST to stay updated on the report's availability or request a free summary

This groundbreaking report will equip you to understand and address barriers to changing prescribing behaviours in Parkinson’s. Beyond identifying challenges, it proposes potential solutions using the unique, validated Healthcare Behaviour Insights Tool (H-BIT) methodology developed by Alpharmaxim and Aston University, UK.

Taking the H-BIT approach, you can radically change the way you plan and execute communications, get the uptake you want and reach patients in need of new options for Parkinson’s treatment.

How will the report support your work in Parkinson’s?

By harnessing the insights of the report, your communications have a greater chance of driving behaviour change and adoption of product, whether you work in Marketing, Medical Affairs, Strategic Planning, Market Access or Clinical Development.

What you’ll get from the report

The H-BIT report will provide valuable detail on the drivers of behaviour that determine physicians’ decision-making, specifically focusing on their capability, opportunity and motivation to change their current behaviour.

Our research shows that when we consider an approach for Parkinson’s, directing communications solely at neurologists will not be effective. Though they are critical in prescribing, much of the support we can give to neurologists may be addressed through changing the prescribing environment – looking again at the provision of clear treatment guidelines and patient journeys, as well as better facilitating the role of non-specialist HCPs.

If these issues are addressed through the behavioural interventions covered in the report, it’s likely that neurologists will have increased capability and motivation to change prescribing patterns, and so the adoption of new therapies may be accelerated.

Many neurologists are slow to adopt new treatments for PD, and the introduction of new disease-modifying treatments will likely slow adoption further. Our report highlights several behavioural components that are responsible. Addressing these underlying challenges with focused intervention will be critical to driving adoption of new treatments.

About Alpharmaxim

Alpharmaxim was founded in 2001, helping cross-functional biopharma teams communicate effectively with clinicians about new medicines or alternative treatment regimes and their potential to improve the patient experience. With a significant focus on pre- and peri-launch work in speciality healthcare, Alpharmaxim has always had a strong awareness of the need to change behaviours and beliefs, and introduced the Belief Continuum® in 2007, with copyright granted in 2016. Alpharmaxim has consistently invested in behavioural science. We have established ARM BeSci Consulting – a specialist team within Alpharmaxim. Working with our academic partners, we have developed a proprietary model that practically evaluates and analyses behaviours and barriers to change. This model also identifies the proven and most effective behaviour change techniques to overcome these barriers. By adopting a behavioural science approach to communications planning, clients can expect targeted communications that achieve greater success, enabling more clarity and ensuring the right patients get the right medicine at the right time.

The report is for individual use and is Copyright Alpharmaxim Limited. All data in the report is owned by Alpharmaxim. Please contact us about multiple-copy discounts.

1. Cure Parkinson’s. Parkinson’s drug therapies in the clinical trial pipeline: 2023 update. https://cureparkinsons.org.uk/2023/06/parkinsons-clinical-trial-pipeline-2023/. Accessed 27 June 2024